Jazz Pharmaceuticals Stock News

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) shares are trading higher by 10.5% at $151.00 after the company reported better-than-expected fourth-quarter EPS and sales results. Jazz Pharmaceuticals report

JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

The Utah Jazz, riding an 8-1 hot streak, can beat any team in the league “when we play together and compete defensively,” according to center Rudy Gobert. They will look to display those qualities on Wednesday when they visit the last-place Houston Rockets. Utah is coming off a 118-114 road victory over the league-leading Phoenix […]

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and

Jazz Pharmaceuticals plc (NASDAQ: JAZZ ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz, delivering over $3 billion in revenue for the first time. Our talented team achieved our goal of five key launches through 2020 and 2021, delivering innovative medicines to patients in critical need. We also acquired and integrated GW Pharmaceuticals, which expanded our commercial portfolio with Epidiolex®, enhanced our R&D capabilities and talent, and added the industry-leading GW cannabinoid platform," said Bruce Cozadd , chairman and CEO of Jazz Pharmaceuticals in a recent press release. "These accomplishments underscore a significant advance in Jazz''s evolution to an innovative global biopharmaceutical company. We expect these achievements, coupled with our expanded capabilities and disciplined capital allocation, to drive sustainable growth and enhanced value as part of Vision 2025, which we announced in January.

Jazz (JAZZ) delivered earnings and revenue surprises of 13.48% and 4.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q4 2021 Results - Earnings Call Transcript

Jazz Pharmaceuticals press release (JAZZ): Q4 Non-GAAP EPS of $4.21 beats by $0.58.Revenue of $896.73M (+34.7% Y/Y) beats by $30.02M.Shares -1.05%.Growing and durable…

DUBLIN, March 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz, delivering over $3 billion in revenue for the…

Jazz (JAZZ) delivered earnings and revenue surprises of 13.48% and 4.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine, Inc. (NASDAQ: EDIT) sai

Jazz Pharmaceuticals (NASDAQ:JAZZ) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is $15.65 (+291.3% Y/Y) and…